Efficacy of Neostigmine as an Adjuvant to Bupivacaine in Ultrasound-guided Transversus Abdominis Plane Block as a Postoperative Analgesia After Caesarean Delivery.

Cesarean birth is a common surgical procedure. After cesarean birth, postsurgical pain may delay recovery, interfere with maternal-newborn bonding, and reduce the breastfeeding if not adequately controlled. Postpartum analgesia has become a common concern.
Many adjuvant drugs used for peripheral nerve blocks as( N-methyl-d-aspartate (NMDA) receptor antagonists , Magnesium , Ephedrine , Dexamesathone , Fentanyl , Midazolam and Neostigmine) The potential of neostigmine as an adjuvant in peripheral nerve block is through its action to increase acetylcholine at muscarinic junctions of peripheral nerves. 500 mcg neostigmine was used as adjuvant to local anesthetic in an axillary brachial plexus block leads to decreased pain and less use of analgesics in the first 24 hours postoperatively with no incidence of adverse effects.

Start Date01 Dec 2025

Sponsor / Collaborator

Mansoura University

NCT06736392

/ Not yet recruitingPhase 2IIT

Efficacy of Dexmedetomidine As an Adjuvant to Bupivacaine in Ultrasound Guided Pericapsular Nerve Group Block for Postoperative Analgesia During Spinal Anesthesia in Hip Replacement Surgeries, a Randomized Controlled Study

Our aim will be to investigate the efficacy of dexmedetomidine as an adjuvant to bupivacaine in ultrasound guided pericapsular nerve group (PENG) block for postoperative analgesia in hip replacement surgeries.
* Our primary outcome of the study: total amount of postoperative morphine consumption in the first 24h postoperative.
* Our secondary outcome of the study: postoperative analgesia assessed by pain score (by Visual Analog Scale)

Start Date01 Mar 2025

Sponsor / Collaborator

Assiut University

NCT06271707

/ Not yet recruitingPhase 4IIT

Left Sided Stellate Ganglion Blocks Impact on the Rate of Post-operative Atrial Fibrillation in Patients Undergoing Thoracic Surgery: A Pilot Study

The purpose of this study is to determine if the addition of an ultrasound guided left sided stellate ganglion block with bupivacaine in patients undergoing esophagectomy, pneumonectomy, or lobectomy will result in lower rates of postoperative atrial fibrillation as compared to standard of care.

Start Date01 Feb 2025

Sponsor / Collaborator

University of Minnesota

100 Clinical Results associated with Bupivacaine

100 Translational Medicine associated with Bupivacaine

100 Patents (Medical) associated with Bupivacaine

14,945

Literatures (Medical) associated with Bupivacaine

01 Dec 2025·Current Pain and Headache Reports

Rhomboid Intercostal and Subserratus Plane Block for Acute Pain Management after Abdominal Surgeries: A Narrative Review

Review

Author: Ly, Gianni H ; Dorius, Bradley ; Boullion, Jolie A ; Kaye, Alan D ; Shekoohi, Sahar ; Robinson, Christopher L ; Patel, Hirni ; Rogers, Brianna N ; Thomassen, Austin S ; Ahmadzadeh, Shahab ; Hollander, Alex V

PURPOSE OF REVIEW:

The rhomboid intercostal and subserratus plane (RISS) block is an effective, safer alternative for managing postoperative acute pain following abdominal surgeries. The RISS block offers several advantages over traditional approaches, including reduced incidence of puncture-related complications, lower rates of systemic opioid consumption, and more consistent analgesic coverage of lower thoracic dermatomes.

RECENT FINDINGS:

Despite a favorable safety profile, the RISS block carries potential risks, such as pneumothorax and local anesthetic systemic toxicity, particularly when long-acting anesthetics such as bupivacaine or ropivacaine are used. Careful administration with ultrasound guidance minimizes these risks, enhancing patient safety. Compared to epidural and paravertebral blocks, RISS is associated with fewer instances of nerve damage, hemodynamic instability, and bleeding. Research suggests that RISS not only improves postoperative pain scores, but also extends duration of analgesic effect, reducing total opioid use by nearly 40%.

CONCLUSION:

Future directions include clinical trials to validate efficacy across diverse patient populations, comparative studies with other regional blocks, and evaluations of long-term outcomes. Expanding our understanding of RISS block application may help advance multimodal pain management protocols, underscoring potential to improve recovery, reduce opioid dependency, and elevate patient quality of life in postoperative settings.

01 Feb 2025·JOURNAL OF CLINICAL ANESTHESIA

Letter to the editor regarding “Recovery quality of transversus abdominis plane block with liposomal bupivacaine after cesarean delivery: A randomized trial”

Letter

Author: Fu, Pinguo ; Yang, Jianjun ; Wang, Xiaocou

01 Feb 2025·JOURNAL OF CLINICAL ANESTHESIA

Intertransverse process block (ITPB) at the retro-superior costotransverse ligament (retro-SCTL) space: Evaluation of local anesthetic spread using MRI and sensory blockade in healthy volunteers

Article

Author: Pakpirom, Jatuporn ; Karmakar, Manoj Kumar ; Siriwanarangsun, Palanan ; Pangthipampai, Pawinee ; Sivakumar, Ranjith Kumar

BACKGROUND:

This study evaluated the spread of a local anesthetic, using MRI and sensory blockade, after an intertransverse process block (ITPB) at the medial aspect of the retro-superior costotransverse ligament (retro-SCTL) space - the medial retro-SCTL space block.

METHODS:

Ten healthy volunteers received a single-injection ultrasound-guided medial retro-SCTL space block at the T4-T5 level using a mixture of 10 ml 0.5 % bupivacaine with 0.5 ml gadolinium. At 15 min, they underwent a high resolution, fat suppressed, T1 weighted MRI scan of the cervicothoracic spine. Loss of sensation to cold was assessed at 15 and 60 min, and then hourly for 5-h, after the block.

RESULTS:

MRI showed consistent (100 %) spread of local anesthetic to the intercostal and paravertebral spaces, anterolateral aspect of the vertebral body (sympathetic chain), costotransverse space, neural foramina, and epidural space in all participants. However, sensory blockade was variable across the ipsilateral hemithorax. Hypoesthesia was more common than anesthesia in both the anterior (median [IQR], 3.5 [2-5] vs 0 [0-1.25], p < 0.001) and posterior (median [IQR], 6[3-7] vs 2[1-3], p < 0.001) hemithorax. Additionally, more dermatomes exhibited anesthesia in the posterior compared to the anterior hemithorax (median [IQR], 2[1-3] vs 0[0-1.25], p = 0.01). A variable number of contralateral dermatomes were also affected in 3 (30 %) volunteers. There was no statistically significant correlation between the local anesthetic spread and the number of hypoesthetic (r = 0.53, p = 0.11) or anesthetic (r = 0.09, p = 0.78) dermatomes on the ipsilateral hemithorax.

CONCLUSIONS:

A single-injection medial retro-SCTL space block, at the T4-T5 level with 10.5 ml of local anesthetic, consistently spreads to the ipsilateral intercostal and paravertebral spaces, sympathetic chain, costotransverse space, neural foramina and epidural space, but produces ipsilateral sensory blockade that is variable and wider over the posterior than anterior hemithorax.

178

News (Medical) associated with Bupivacaine

07 Jan 2025

·www.globenewswire.com

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is an innovative, FDA-cleared, drug-free treatment that relieves pain via cryoneurolysis—a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals. Pain relief is typically experienced immediately after treatment, with the effects lasting for months as the nerve gradually regenerates. To date, the ioveraº portfolio has consisted of either a three-pronged Smart Tip featuring 8.5-mm long 27-gauge needles to treat superficial nerves or a single, 90-mm long, 20-guage Smart Tip ideally suited to treat deeper nerves. It is most commonly used to treat knee pain, but frequently used to manage pain in the hip, shoulder, chest, foot and ankle, and more. Now, this new, 25-gauge 180-mm Smart Tip will allow for the treatment of deeper nerves, such as the medial branch nerve and is specifically designed so that it can relieve chronic low back pain associated with facet mediated pain. This longer-needle Smart Tip is uniquely designed for use through a cannula or introducer, providing the ability for ice ball formation at deeper peripheral nerves. Chronic low back pain remains a pervasive health challenge in the United States: Back pain is the leading cause of disability nationwide.It is also the most common reason for extended work absences.Chronic back pain is the number one indication for opioid prescriptions, often leading to dependency and abuse.Annually, 28 to 30 million Americans seek treatment for chronic back pain, yet only 2 to 3 million undergo interventional procedures. With the introduction of this new iovera° Smart Tip, Pacira aims to address these gaps and elevate the standard of care. This FDA-cleared innovation offers a compelling alternative to conventional treatments such as radiofrequency ablation (RFA) ablation, which has substantial limitations. With RFA, patients may not get the effects of pain relief until 1-2 weeks after treatment, further the intense heat can damage surrounding tissue and blood vessels, and tissue damage may lead to painful neuritis (inflammation in the nerves). A single-center randomized pilot study conducted by Interventional Pain Management and Physical Medicine and Rehabilitation (PM&R) Specialist Martin Ferrillo, DO, of Albany and Saratoga Centers for Pain Management, compared iovera° cryoneurolysis to RFA for facet-mediated chronic back pain. The findings underscore the significant advantages of the iovera° system: Patients treated with iovera° reported pain scores that were more than 2 points lower at 180 and 360 days compared to those treated with RFA on the 0-10 NRS Pain scale.At 360 days, patients in the iovera° group showed statistically and clinically significant improvements in functional outcomes, as evidenced by average Oswestry Disability Index (ODI) scores improving from moderate disability to minimal disability.More iovera° patients expressed satisfaction with their pain management compared to those receiving RFA.No serious adverse events were observed over the course of the study. “The FDA clearance of this new iovera° Smart Tip is a pivotal step forward, offering patients an innovative, drug-free solution that delivers meaningful and lasting pain relief” said Jonathan Slonin, MD, Chief Medical Officer of Pacira BioSciences. “This achievement reflects our dedication to improving quality of life for the millions of Americans living with chronic back pain.” About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com. About iovera°® The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. In one study, the majority of the patients suffering from osteoarthritis of the knee experienced pain and system relief beyond 150 days. When stimulation compatible components are used, the iovera° system can also facilitate targeting nerve location by conducting electrical nerve stimulation from a compatible 3rd party nerve stimulator. The iovera° system is not indicated for treatment of central nervous system tissue. Important Safety Information Do not receive treatment with iovera° if you experience hypersensitivity to cold or have open and/or infected wounds near the treatment site.You may experience bruising, swelling, inflammation and/or redness, local pain and/or tenderness, and altered feeling at the site of application.In treatment area(s), you may experience damage to the skin, skin darkening or lightening, and dimples in the skin.You may experience a temporary loss of your ability to use your muscles normally outside of the treatment area.Talk to your doctor before receiving treatment with iovera°. Forward-Looking Statements Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our future outlook, our intellectual property and patent terms, our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the integration of our new chief executive officer; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the ability to successfully integrate any future acquisitions into our existing business; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the “SEC”). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Clinical ResultDrug Approval

20 Dec 2024

·www.globenewswire.com

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical’s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. “We are encouraged to see that the product will advance to Phase 3 trials in painful lumbosacral radiculopathy, pending discussions with regulators,” said Eric Lang, Channel’s Chief Medical Officer. “While both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that an over expression of NaV1.8 leads to moderate pain whereas an overexpression of NaV1.7 leads to debilitating pain morbidities, and we believe that NaV1.7 inhibition may be a more potent therapy for pain treatment.” Characteristics of Selective NaV1.7 Inhibition NaV1.7 is a well-studied drug target with strong genetic validation — studies of inheritable pain disorders demonstrate that the spectrum of NaV1.7 activity validates the importance of this target. Lack of NaV1.7 activity leads to the inability to sense pain, whereas NaV1.7 gain of function leads to severe pain. Modulation of NaV1.7, therefore, should be an effective mechanism for decreasing pain. “Channel Therapeutics has chosen a three-pronged approach for our NaV1.7 molecule to demonstrate the utility of this target. We are utilizing an oral NaV1.7 inhibitor for the potential treatment of neuropathic pain starting with Idiopathic Small Fiber neuropathy and Erythromelalgia, a novel eye drop formulation of a NaV1.7 inhibitor to treat eye pain and a novel slow-release depot formulation NaV1.7 inhibitor for post-surgical nerve blocks,” stated Frank Knuettel II, Chief Executive Officer of Channel. “The important differences between NaV1.7 and NaV1.8 not only informs but also differentiates Channel Therapeutics’ approaches to clinical development of the Company’s selective sodium channel blockers CC8464, CT2000 and CT3000. We are very encouraged by the recent data that we have seen from our ongoing programs, including the results from our in vivo nerve block results published earlier this week. As such, we look forward to the upcoming studies and data readouts in 2025 which will serve as critical milestones for which to further substantiate the merits of Channel’s clinical development plan,” Mr. Knuettel concluded. About Channel Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit www.channeltherapeutics.com or follow us on social media. Forward-Looking Statements This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the Company’s belief that nerve blocks with its NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain, (ii) the Company’s belief the Company’s NaV1.7 inhibitor has the potential to improve on existing postoperative therapeutic options while opening the door for success with the Company’s other programs, (iii) the Company’s belief that the NaV1.7 inhibitor may offer a better option for post-surgical physical therapy as compared to bupivacaine, (iv) the Company’s belief that investors should feel encouraged that the Company has a strong development path towards successfully launching drugs with considerable market opportunities, and (iv) the timing of expected results on the Company’s eye drops for the treatment of various types of eye pain. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value or that the Company’s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law. Channel Media and Investor Inquiries:Mike MoyerManaging Director, LifeSci Advisors, LLCmmoyer@lifesciadvisors.com

Phase 2

18 Dec 2024

·www.globenewswire.com

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it achieved its endpoints in two pre-clinical in vivo models of the Company’s nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration. “We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain,” stated Dr. Eric Lang, Chief Medical Officer of Channel. “Additionally, we believe this drug has the potential to improve on existing postoperative therapeutic options while opening the door for success with our other programs,” concluded Dr. Lang. About the trial The Company performed a thermal hyperalgesia test in rodents with a placebo arm, bupivacaine arm and four arms of the main formulations of the Company’s molecule. The Company also performed a mechanical allodynia test in rodents with the same arms as above. For both models, the drugs were administered as a sciatic nerve block. All four Company formulations showed a depot effect in excess of four days, an improvement over bupivacaine, the current standard of care. Results The results of the thermal hyperalgesia results are shown in the chart below. After thirty minutes, three of the four formulations showed materially better efficacy than bupivacaine, with each of the three being statistically superior to placebo for more than two days longer than bupivacaine. One of the formulations remained statistically superior to placebo for more than four days. Further, as NaV1.7 does not have an impact on mobility, this approach may offer a better option for post-surgical physical therapy as current nerve block therapies cause temporary paralysis in the affected area. Similarly for the mechanical allodynia test results, three of the four formulations showed statistically better efficacy for a longer duration of time than bupivacaine. The mechanical allodynia test is shorter in duration, reflecting the subject’s innate swift recovery rate to surgical incisions. Nonetheless, the results mirrored the successful results set forth with the thermal hyperalgesia test. “These results support our belief that NaV1.7 is a potent and effective target for the development of drugs for the treatment of pain,” stated Frank Knuettel II, Chief Executive Officer of Channel. “With these results, investors should feel encouraged that we have a strong development path towards successfully launching drugs with considerable market opportunities,” Mr. Knuettel concluded. According to BioSpace, the post-operative global pain market was valued at $2.6 billion in 2023, of which, Exparel, a bupivacaine liposome injectable suspension, generated approximately $538 million in revenue. It is this existing market that the Company is tackling, as well as the post-surgical opioid market opportunity, as these results show potential efficacy for a long period of time, which should reduce post-surgical opioid usage. Results are expected for the studies conducted on the Company’s eye drops for the treatment of various types of eye pain – including severe dry eye, corneal abrasions, surgical intervention and other indications – in late January 2025. About Channel Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit www.channeltherapeutics.com or follow us on social media. Forward-Looking Statements This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the Company’s belief that nerve blocks with its NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain, (ii) the Company’s belief the Company’s NaV1.7 inhibitor has the potential to improve on existing postoperative therapeutic options while opening the door for success with the Company’s other programs, (iii) the Company’s belief that the NaV1.7 inhibitor may offer a better option for post-surgical physical therapy as compared to bupivacaine, (iv) the Company’s belief that investors should feel encouraged that the Company has a strong development path towards successfully launching drugs with considerable market opportunities, and (iv) the timing of expected results on the Company’s eye drops for the treatment of various types of eye pain. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value or that the Company’s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law. Channel Media and Investor Inquires: For Investor Inquiries:Mike MoyerManaging Director, LifeSci Advisors, LLCmmoyer@lifesciadvisors.com

Clinical Result

100 Deals associated with Bupivacaine

External Link

KEGG	Wiki	ATC	Drug Bank
D07552	Bupivacaine	N01BB01	DB00297

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	US	Pacira Biosciences, Inc.	28 Oct 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Back Pain	Phase 3	US	Pacira Biosciences, Inc.	30 Apr 2024
Complication	Phase 3	US	Pacira Biosciences, Inc.	30 Apr 2024
Osteoarthritis, Knee	Phase 3	US	Pacira Biosciences, Inc.	18 Jan 2022
Nausea	Phase 3	US	Pacira Biosciences, Inc.	22 Oct 2021
Pain	Phase 3	US	Pacira Biosciences, Inc.	22 Oct 2021
Analgesia	Phase 3	US	Pacira Biosciences, Inc.	14 Apr 2021
Leg Injuries	Phase 3	US	Pacira Biosciences, Inc.	20 Oct 2020
Ankylosis	Phase 3	-	Pacira Biosciences, Inc.	15 Jun 2020
Metatarsus Varus	Phase 3	-	Pacira Biosciences, Inc.	15 Jun 2020
Shoulder Pain	Phase 3	-	Pacira Biosciences, Inc.	01 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04867369 (CTgov)	Phase 4	Tendinopathy	160	Bupivacaine 20mL 0.5% (Pecs II Block)	ohuinqjpye(gsgfdjvasy) = ohazmdjopw fajzdaksck (yaaiezmeeq, nqklwrsmjx - dtogcltbai) View more	-	13 Dec 2024
				Bupivacaine up to 15mL 0.25% (Surgical Infiltration)	ohuinqjpye(gsgfdjvasy) = shlqxbftwr fajzdaksck (yaaiezmeeq, hvgtwprrsz - fewdygwyfr) View more
NCT04996251 (CLAPPS, CTgov)	Phase 4	Pain, Postoperative	129	Bupivacaine Injection (Subcutaneous Infiltration Pre-incision)	nlfvcllwqx(qzxwdzcuon) = jvpvycxnyw zjgohalytz (ybglnpdapz, aknjbytlpc - aifvtyfhpv) View more	-	10 Dec 2024
				Bupivacaine Injection (Subcutaneous Infiltration Post-incision)	nlfvcllwqx(qzxwdzcuon) = jbjcsxoihi zjgohalytz (ybglnpdapz, fpzcshdmce - yshulziwnh) View more
NCT04364867 (CTgov)	Phase 4	Pain, Postoperative	102	Exparel (Exparel)	gfywxalmrp(twukvjasim) = akcwausunp szloicsxtv (znlqxglcxu, dbseazveld - idzhdoduno) View more	-	26 Nov 2024
				Pain Pump (Pain Pump)	gfywxalmrp(twukvjasim) = ciutsblapk szloicsxtv (znlqxglcxu, vdmygbrgfp - eqtfmnkadu) View more
NCT04928339 (CTgov)	Phase 4	-	100	Liposomal Bupivacaine (PIFB Intervention)	azvkmryael(fyxgnalvgc) = ifmtggygpb yyerzwsaks (yajtorybfv, dgplostsdr - smobuvdytd) View more	-	19 Nov 2024
				saline (Saline Control)	azvkmryael(fyxgnalvgc) = trijsasspc yyerzwsaks (yajtorybfv, jxqgnzmald - bbylpxeejo) View more
NCT05068661 (CTgov)	Phase 4	Labor Pain	101	Ropivacaine 0.1% Injectable Solution+Bupivacaine 0.25% Injectable Solution (Combined Spinal Epidural)	tbmvszlfzm(mvkabweadr) = ajwyrosjvw mavorfsnmp (zlrarmeqrz, sbjpwthack - dpawjmzwfs) View more	-	06 Nov 2024
				Ropivacaine 0.1% Injectable Solution (Dural Puncture Epidural)	tbmvszlfzm(mvkabweadr) = omziyadjnv mavorfsnmp (zlrarmeqrz, pkbwpmiunl - kfhgmsvtbr) View more
NCT05139030 (CTgov)	Phase 3	Osteoarthritis, Knee \| Pain, Postoperative	167	EXPAREL (Cohort 1 + 2 EXPAREL ADMIX ARM)	fomqksgyll(hknhtbqedp) = lmrsbdduoh rtgalsyrvc (czjahrnfpu, xrechnsdaw - brdbophnyo) View more	-	24 Oct 2024
				BUPIVACAINE (Cohort 1 + 2 BUPIVACAINE HCI ARM)	fomqksgyll(hknhtbqedp) = pgjpeqtdou rtgalsyrvc (czjahrnfpu, rblbjqgzgn - snrbgxiwci) View more
NCT04258631 (CTgov)	Phase 4	Female Genital Neoplasms \| Pain	105	Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine))	hnbnewffrn(uhdbijgzeq) = skxfuorqqg kxmktkcuen (dnnayqixhf, wvmfbfhchq - pyjajndvew) View more	-	16 Oct 2024
				Laparotomy+Hydromorphone+Liposomal Bupivacaine (Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone))	hnbnewffrn(uhdbijgzeq) = yrkkmyclyo kxmktkcuen (dnnayqixhf, iazmgzxodk - bsautznmzv) View more
NCT04777591 (Pubmed \| Plast Reconstr Surg)	Phase 4	-	117	Bupivacaine and Epinephrine TAP block	bawycyontb(atkihznbkc) = semkjndwyf dirnrcywvn (dsdcmfvrwo ) View more	Negative	01 Oct 2024
				Liposomal Bupivacaine, Bupivacaine, and Epinephrine TAP block	bawycyontb(atkihznbkc) = jmcsflwlsr dirnrcywvn (dsdcmfvrwo ) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	wclxzyiaws(byijrhlrrb) = onkvxnhqqv aqxcgrfvai (ckehjulhpp, oftdajlyfw - irlgzznbje) View more	-	19 Sep 2024
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	wclxzyiaws(byijrhlrrb) = zhfynsfgmv aqxcgrfvai (ckehjulhpp, svfzvfkpnc - yuptrpbfee) View more
NCT05767749 (CTgov)	Phase 4	Anesthesia	75	Ropivacaine+Epinephrine+Lidocaine (Lidocaine+Epinephrine (vs Ropivacaine))	nrsqvuvvmh(eyswmdsybg) = csrxkfyejh nybdnbgjsu (wuybdopsxv, hyonjcjpqe - uzskpiqblu) View more	-	19 Sep 2024
				Ropivacaine+Epinephrine+Lidocaine (Ropivacaine (vs Lidocaine+Epinephrine))	nrsqvuvvmh(eyswmdsybg) = ncczdmrrag nybdnbgjsu (wuybdopsxv, pngyonibzi - tyardoeftt) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis